Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | GFER | P55789 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 11/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.56 |
| ▸ | GAA | P10253 | 6/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.52 |
| ▸ | TP53 | P04637 | 4/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | RECQL | P46063 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2174874 | 0.98 | MAPT (0.58) | CYP1A2CYP3A4CYP2C19GFERMAPT | |
| SCHEMBL17361558 | 0.93 | MAPT (0.53) | CYP1A2CYP3A4CYP2C19GFERMAPT | |
| SCHEMBL3823870 | 0.86 | CYP1A2 (0.59) | CYP1A2CYP3A4CYP2C19GFERMAPT | |
| SCHEMBL13679676 | 0.84 | MAPT (0.46) | CYP1A2CYP3A4CYP2C19GFERMAPT | |
| SCHEMBL3829982 | 0.84 | MAPT (0.58) | CYP1A2CYP3A4CYP2C19GFERMAPT | |
| SCHEMBL22198292 | 0.82 | CA12 (0.49) | CYP1A2CYP3A4CYP2C19GFERMAPT | |
| SCHEMBL14431554 | 0.82 | CYP1A2 (0.58) | CYP1A2CYP3A4CYP2C19GFERMAPT | |
| SCHEMBL2264251 | 0.81 | ADRA2C (0.59) | GFERMAPTALDH1A1GAAKDM4E | |
| SCHEMBL487498 | 0.81 | GAA (0.56) | CYP1A2MAPTALDH1A1GAAKDM4E | |
| SCHEMBL6887590 | 0.81 | ALDH1A1 (0.71) | CYP1A2CYP3A4CYP2C19GFERMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114401954-A | Piperidinylamine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2022-04-26 | — | — | CN | claimed |
| EP-4466260-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2024-11-27 | — | — | EP | disclosed |
| WO-2024124002-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | THIRD HARMONIC BIO, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2023139199-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023091644-A2 | HSD17B13-RELATED DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023049218-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-03-30 | — | — | WO | disclosed |
| US-20230041761-A1 | SMALL MOLECULE MODULATORS OF SIGMA-1 AND SIGMA-2 RECEPTORS AND USES THEREOF | NORTHWESTERN UNIVERSITY | 2023-02-09 | — | — | US | disclosed |
| US-20220204452-A1 | ANTIMALARIAL COMPOUNDS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. | 2022-06-30 | — | — | US | disclosed |
| CN-114401954-A | Piperidinylamine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2022-04-26 | — | — | CN | disclosed |
| WO-2021145582-A1 | MONO-AZO DICHROIC DYE COMPOUND, POLARIZING PLATE COMPOSITION COMPRISING SAME, POLARIZING PLATE FORMED THEREFROM, AND OPTICAL DEVICE COMPRISING SAME | 주식회사 엘지화학 | 2021-07-22 | — | — | WO | disclosed |
| EP-1138673-A2 | Novel carbamates and ureas as modifiers of multi-drug resistance | Vertex Pharmaceuticals Incorporated (US) | 2001-10-04 | — | — | EP | disclosed |
| EP-1115704-A1 | NOVEL SUBSTITUTED INDOLINONES WITH AN INHIBITORY EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES | Boehringer Ingelheim Pharma KG (DE) | 2001-07-18 | — | — | EP | disclosed |
| CN-1303374-A | Substituted indolinones, process for their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA (DE) | 2001-07-11 | — | — | CN | disclosed |
| WO-2000018734-A1 | NOVEL SUBSTITUTED INDOLINONES WITH AN INHIBITORY EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-04-06 | — | — | WO | disclosed |
| EP-0941113-A1 | METHODS AND COMPOSITIONS FOR STIMULATING NEURITE GROWTH USING COMPOUNDS WITH AFFINITY FOR FKBP12 IN COMBINATION WITH NEUROTROPHIC FACTORS | Vertex Pharmaceuticals Incorporated (US) | 1999-09-15 | — | — | EP | disclosed |
| US-5780484-A | Methods for stimulating neurite growth with piperidine compounds | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1998-07-14 | — | — | US | disclosed |
| WO-1998020893-A1 | METHODS AND COMPOSITIONS FOR STIMULATING NEURITE GROWTH USING COMPOUNDS WITH AFFINITY FOR FKBP12 IN COMBINATION WITH NEUROTROPHIC FACTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1998-05-22 | — | — | WO | disclosed |
| US-5744485-A | INCREASE SENSITIVITY OF CELLS; CANCER | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1998-04-28 | — | — | US | disclosed |
| EP-0754176-A1 | NOVEL CARBAMATES AND UREAS AS MODIFIERS OF MULTI-DRUG RESISTANCE | Vertex Pharmaceuticals Incorporated (US) | 1997-01-22 | — | — | EP | disclosed |
| WO-1995026337-A1 | NOVEL CARBAMATES AND UREAS AS MODIFIERS OF MULTI-DRUG RESISTANCE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1995-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204452-A1 | ANTIMALARIAL COMPOUNDS | H1-3, FPR3, NHERF1 | CYP1A2 255/4885CYP3A4 556/4885CYP2C19 287/4885 |
| US-20230041761-A1 | SMALL MOLECULE MODULATORS OF SIGMA-1 AND SIGMA-2 RECEPTORS AND USES THEREOF | SIGMAR1, TMEM97, OPRM1 | CYP1A2 58/4885CYP3A4 658/4885CYP2C19 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.